Bookmark and Share

9 Cheap Dividend Pharma Stocks

When investors are on the hunt for income-driving dividend stocks, they often gravitate toward utilities or consumer staples names. And well they should. Those businesses are essentially recession- proof, so the income — in the form of dividends — they pass along to shareholders is quite reliable.

Conversely, pharmaceutical stocks are rarely seen as effective dividend stocks. Although drugs are also relatively non-cyclical, these stocks are often impacted by an ever-changing regulatory environment and the ever-changing strength or weakness of a drugmaker’s portfolio and pipeline.

As it turns out, however, some of the best-known Big Pharma names are also very solid dividend providers. These drugmakers dole out income to shareholders by leveraging their size to constantly refresh their drug portfolios. 

In fact, the average dividend yield for all the major pharma stocks right now (and bear in mind there are some that pay nothing) is a healthy 2.35%. That’s still less than the typical 4% payout utility stocks boast right now.

Attached I've compiled a list of the highest yielding stocks with a low  P/E within the pharma subindustry. Only 9 names exist.

Here are the results...

16 Long-Term Dividend Growers At Reasonable Prices

A very, very famous investor once said that he liked to buy excellent businesses at 'reasonable prices.' I like to think that I am of the same mindset. A strategy of mine is to look for such businesses with real competitive advantages, but ones that are dividend payers and dividend growers.

My watch list now includes a couple hundred stocks, all of which are dividend payers. Today I'd like to share a small list of those which I believe retail income investors can buy 'off the shelf' right now.

These are the results...

Warren Buffett Buys And Sells These Stocks Surprisingly

Warren Buffett and his team of portfolio managers listed some 148 positions worth a whopping $147.9 billion in equities in the official Form 13F filing with the Securities and Exchange Commission. This compared to $128.8 billion as of the end of the third quarter of 2016 and $115.46 billion as of December 31.

It is important to understand that some changes are made by Warren Buffett himself, with 14 sub-entities of Berkshire Hathaway in prior filings. Other changes may have come from the likes of newer portfolio managers Ted Weschler and Todd Combs. It appears as though the Buffett portfolio managers have been given much larger investing amounts.

If there is one key takeaway for the 2017 stocks it would be that this was one of the largest changes we have seen in years. New stakes were added and other stakes were grown. Other stakes were cleaned out or decreased.

Attached you will find a small overview of Warren Buffett's latest stock buys and sells during Q4 in 2016...